JERUSALEM, July 30 (Reuters) - The CEO of Israel's Teva

Pharmaceutical Industries said on Wednesday there was

"big ambiguity" and "so many unanswered questions" in the drugs

sector regarding potential U.S. tariffs, but the company was

positioned for minimal impact.

Richard Francis said 70% of Teva's generics business was

outside of the United States while most of its branded drugs

business was in the U.S., with its largest drug - Huntington's

Disease treatment Austedo - manufactured there.

He told Reuters after Teva issued second-quarter

earnings that it had a favourable supply chain - no reliance on

China and very little in India. "Those aspects just set us up in

the face of this change, probably a lot better than our

competitors," he said.

"I feel we have the ability to put ourselves in a good

position here, with the caveat - I need to know the details."